Market Overview

XenoPort Announces New Employment Inducement Award

Share:
SANTA CLARA, Calif.--(BUSINESS WIRE)--

XenoPort, Inc. (Nasdaq: XNPT) reported today that an equity award was made to a new employee subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan. The employee, Jyothi Tammineni, was granted restricted stock units representing an aggregate of 750 shares of XenoPort's common stock. The restricted stock units vest in four equal annual installments on anniversaries of the November 1, 2012 grant date. The equity award was approved by the independent compensation committee of XenoPort's board of directors and was granted as an inducement material to the new employee entering into employment with XenoPort in accordance with Nasdaq Market Place Rule 5635(c)(4).

About XenoPort

XenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved in the United States for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults and for the management of postherpetic neuralgia in adults. GlaxoSmithKline holds commercialization rights and certain development rights for Horizant in the United States. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved for the treatment of RLS in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and five other Asian countries. XenoPort holds all other world-wide rights and has co-promotion and certain development rights to gabapentin enacarbil in the United States. XenoPort's pipeline of product candidates includes potential treatments for patients with spasticity, Parkinson's disease and relapsing-remitting multiple sclerosis.

To learn more about XenoPort, please visit the Web site at www.XenoPort.com.

XENOPORT and Regnite are registered trademarks of XenoPort, Inc.

Horizant is a registered U.S. trademark of GlaxoSmithKline.

XNPT2G

XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com

View Comments and Join the Discussion!